Taldefgrobep Alfa in Adults With Overweight and Obesity
Public ClinicalTrials.gov record NCT07281495. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With Open-Label Extension to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Taldefgrobep Alfa in Adults Living With Overweight and Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Study identification
- NCT ID
- NCT07281495
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 24, 2025 (Actual)
- Primary completion
- Sep 2026 (Estimated)
- Completion
- Sep 2026 (Estimated)
- Last update posted
- Mar 20, 2026
2025 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site-001 | Chula Vista | California | 91911 | — |
| Site-014 | Montclair | California | 97163 | — |
| Site-011 | Sacramento | California | 95821 | — |
| Site-018 | Tustin | California | 92780 | — |
| Site-020 | Orlando | Florida | 32804 | — |
| Site-008 | Palm Springs | Florida | 33461 | — |
| Site-015 | St. Petersburg | Florida | 33704 | — |
| Site-007 | Chicago | Illinois | 60625 | — |
| Site-016 | Indianapolis | Indiana | 46254 | — |
| Site-010 | Baton Rouge | Louisiana | 70808 | — |
| Site-009 | Metairie | Louisiana | 70006 | — |
| Site-006 | City of Saint Peters | Missouri | 63303 | — |
| Site-003 | Springfield | Missouri | 65807 | — |
| Site-019 | Monroe | North Carolina | 28112 | — |
| Site-002 | Fargo | North Dakota | 58104 | — |
| Site-017 | North Charleston | South Carolina | 29405 | — |
| Site-005 | Austin | Texas | 78745 | — |
| Site-012 | McKinney | Texas | 75069 | — |
| Site-013 | San Antonio | Texas | 78229 | — |
| Site-004 | Arlington | Virginia | 22205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07281495, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2026 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07281495 live on ClinicalTrials.gov.